Treats major depressive disorder. ANDA 206250, held by Cadila Pharmaceuticals. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 206250 (Venlafaxine Hydrochloride), held by Cadila Pharmaceuticals, was first approved by FDA on Nov 21, 2018, with 3 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Venlafaxine tablets are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2018 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 25MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 37.5MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 50MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 100MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Rx |
| Aug 18, 2023 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Sep 20, 2021 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Sep 3, 2021 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Nov 21, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters